VILPOWER D 100/10 TAB

About

VILPOWER D 100/10 TAB is a combination medication likely containing Vildagliptin and Dapagliflozin, indicated for the treatment of type 2 diabetes mellitus. Vildagliptin, a DPP-4 inhibitor, enhances the body's natural ability to control blood glucose by increasing active incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. Dapagliflozin, an SGLT2 inhibitor, works by reducing glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine. This dual mechanism of action provides complementary pathways to lower blood glucose levels, offering comprehensive glycemic control. Additionally, Dapagliflozin contributes to cardiovascular and renal benefits, making this combination a valuable option for patients needing multi-faceted diabetes management.

Uses

• Management of type 2 diabetes mellitus
• Improvement of glycemic control
• Cardiovascular risk reduction (Dapagliflozin)
• Renal protection (Dapagliflozin)

Directions For Use

Take orally, usually once daily in the morning, with or without food, as prescribed by your physician.

Benefits

• Significant reduction in HbA1c levels
• Weight loss and blood pressure reduction
• Reduced risk of major adverse cardiovascular events
• Delayed progression of kidney disease
• Low risk of hypoglycemia
• Complementary mechanisms for robust glucose control

Side Effects

• Urinary tract infections
• Genital yeast infections
• Increased urination
• Thirst
• Dizziness
• Nasopharyngitis
• Headache
• Back pain
• Hypoglycemia (rare)
• Ketoacidosis (rare)
• Dehydration
• Flu-like symptoms

Safety Measures

• Alcohol - Use with caution; can increase risk of dehydration and may affect blood sugar levels.
• Pregnancy - Not recommended during pregnancy; consult your doctor. Potential for adverse effects on fetal kidney development.
• Breastfeeding - Not recommended during breastfeeding; consult your doctor. Unknown if excreted in human milk.
• Liver - Use with caution; no dose adjustment typically needed for mild-moderate impairment.
• Kidney - Not recommended in severe renal impairment (eGFR <30 mL/min/1.73m²).
• Lung - Generally safe, but monitor for dehydration in patients with compromised respiratory status.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.